MMA embolization is a minimally invasive procedure that blocks blood flow through the middle meningeal artery to treat chronic subdural hematomas, which are collections of old blood trapped between the brain and its outer covering. The procedure takes roughly 45 minutes to an hour, requires only mild sedation, and has emerged as a powerful alternative or addition to traditional brain surgery for this condition. In systematic reviews, it has achieved hematoma resolution in nearly 97% of cases.
Why the Middle Meningeal Artery Matters
A chronic subdural hematoma (cSDH) forms when blood slowly accumulates in the space between the brain and the dura, the tough membrane that surrounds it. This typically happens after a head injury, sometimes one so minor the person doesn’t remember it. The body tries to reabsorb the blood by growing tiny, fragile membranes around it, but those membranes have a poor blood supply of their own and tend to leak, feeding the hematoma with fresh blood and keeping it from resolving.
The middle meningeal artery is the main blood vessel supplying the dura and those leaky membranes. By permanently blocking this artery, embolization cuts off the fuel source that keeps the hematoma growing. Without a fresh blood supply, the trapped fluid gradually reabsorbs on its own.
How the Procedure Works
You receive a mild sedative that keeps you relaxed but awake. An endovascular neurosurgeon numbs a small area of skin at your wrist or groin to access an artery, then inserts a catheter, a thin flexible tube about the width of a strand of spaghetti. Using real-time X-ray imaging, the surgeon threads the catheter through your blood vessels up to the middle meningeal artery near the hematoma.
Once in position, the surgeon injects a blocking agent that permanently seals off the artery. This can be a medical-grade glue, tiny particles, or platinum microcoils. After the artery is closed, the catheter is withdrawn and the small incision is closed. The entire process typically takes 45 minutes to an hour, though wrist access tends to add about 10 extra minutes on average compared to groin access.
Both access points produce comparable outcomes and complication rates. Wrist access avoids the need to lie flat for several hours afterward, which some patients prefer. In about 1% of wrist-access cases, surgeons need to switch to the groin approach during the procedure.
Who Benefits Most
Chronic subdural hematomas are most common in older adults, with a typical age at presentation around 68 to 69 years. Risk factors include advanced age, male sex, blood-thinning medications, alcohol use, and conditions that impair clotting. The incidence is rising as the population ages and more people take anticoagulants for heart conditions, prior strokes, or blood clots.
MMA embolization is particularly useful in several scenarios. One of the most common is recurrence after conventional surgery. Traditional burr-hole drainage has recurrence rates as high as 30%, and many patients referred for embolization have already had one or two failed surgical evacuations. Embolization addresses the underlying blood supply problem that surgery alone does not.
The procedure also fills an important gap for patients who need to stay on or quickly resume blood thinners. After traditional surgery, anticoagulants typically must be held for a prolonged period, which creates serious risk for people with mechanical heart valves, recent strokes, or dangerous blood clots. MMA embolization may allow these medications to be restarted much earlier. It can also serve as a standalone treatment for patients who are too medically fragile for surgery under general anesthesia, including those with very low platelet counts or other conditions that make open procedures risky.
Effectiveness Compared to Surgery
A comprehensive meta-analysis found that embolization alone reduced the odds of hematoma recurrence by about 61% compared to surgery alone. When used as an add-on to surgery, it showed a similar benefit, cutting recurrence odds by roughly 60%. These are substantial improvements over the traditional surgical approach, which has long been the standard but carries frustratingly high recurrence rates.
One systematic review of 190 patients reported hematoma resolution in 96.8% of cases with no procedure-related complications. Multiple randomized controlled trials have now confirmed that MMA embolization is an effective adjunctive therapy for patients with stable neurological symptoms. A 2024 consensus statement from the ARISE I group recognized this high-level evidence and noted that ongoing pooled analyses will further refine which patients benefit most.
Risks and Safety Profile
The safety record has been strong in published studies, but the procedure does carry real anatomical risks that require an experienced operator. The middle meningeal artery has connections to other critical blood vessels, and blocking the wrong branch can have serious consequences.
The most significant concern involves connections between the middle meningeal artery and the ophthalmic artery, which supplies the eye. If blocking material travels into these connections, it can cause blindness. The artery also has branches that supply the facial nerve inside the skull bone. Embolizing too close to these branches can damage the nerve, potentially causing facial weakness. In rare anatomical variants, the middle meningeal artery connects to major arteries supplying the brain itself, which could theoretically lead to stroke if material refluxes into them.
These risks are why detailed imaging before and during the procedure is essential. The surgeon performs careful angiography to map the patient’s specific vascular anatomy and identify any dangerous connections before injecting blocking material. When the artery has an unusual origin from the ophthalmic artery, embolization may not be safe and the procedure is avoided entirely.
Recovery and Follow-Up
Recovery is considerably lighter than after traditional brain surgery. There is no large incision, no hole drilled in the skull, and no general anesthesia in most cases. Patients typically experience minimal pain at the catheter insertion site.
Follow-up imaging is recommended on a specific schedule: a scan at 24 hours after the procedure, then again at 1 month, 3 months, and 6 months. These scans track whether the hematoma is shrinking as expected and check for any signs of recurrence or complications. The hematoma does not disappear immediately. It reabsorbs gradually over weeks to months as the cut-off blood supply allows the body’s natural cleanup processes to work. In some cases, MRI or specialized CT imaging is used to evaluate the membranes around the hematoma and confirm they are no longer active.
Because the procedure targets the root cause of recurrence rather than simply draining accumulated fluid, the long-term outlook is favorable. For patients who previously faced repeated surgeries for recurring hematomas, embolization often breaks the cycle.